How the Lixte Biotechnology Holdings and dostarlimab study could influence future ovarian cancer trial design
Lixte Biotechnology’s LB-100 ovarian cancer data may signal a new immunotherapy pathway. Read what this could change for the sector.
Why Corcept Therapeutics now faces a bigger execution test after Lifyorli’s ROSELLA success
Corcept Therapeutics’ Lifyorli showed strong survival benefit in ovarian cancer. Read what the ROSELLA data could change for clinicians and payers.
Whitehawk Therapeutics sharpens HWK-016 case as MUC16 emerges as a stronger ADC target in gynecologic cancers
Whitehawk Therapeutics says new MUC16 data support HWK-016 in gynecologic cancers. Read what this could change for ADC development.